[Skip to Navigation]
March 2017

Important Questions About Lung Cancer Screening Programs When Incidental Findings Exceed Lung Cancer Nodules by 40 to 1

Author Affiliations
  • 1Editor, JAMA Internal Medicine
  • 2Department of Medicine, University of California, San Francisco
  • 3Deputy Editor, JAMA Internal Medicine
  • 4Division of General Internal Medicine, Uniformed Services University, Bethesda, Maryland
JAMA Intern Med. 2017;177(3):311-312. doi:10.1001/jamainternmed.2016.9446

Lung cancer screening (LCS) programs have been growing in number in the last few years, since the US Preventive Services Task Force gave LCS a grade B recommendation in 2013,1 based primarily on the National Lung Screening Trial (NLST) findings.2 Thereafter, on February 5, 2015, the Centers for Medicare & Medicaid Services (CMS) decided to provide coverage for LCS in smokers aged 55 to 77 years, recommending the use of a decision aid in screening implementation (https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274).